Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CBFB | Q13951 | 1/20 | 0.38 |
| ▸ | SMO | Q99835 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 2/20 | 0.35 |
| ▸ | CDK4 | P11802 | 1/20 | 0.35 |
| ▸ | CCND1 | P24385 | 1/20 | 0.35 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23999947 | 0.95 | PDPK1 (0.41) | PDPK1MAPTPOLBTSHRMAPK1 | |
| SCHEMBL24003965 | 0.95 | PDPK1 (0.41) | PDPK1MAPTPOLBTSHRMAPK1 | |
| SCHEMBL30180421 | 0.95 | PDPK1 (0.41) | PDPK1MAPTPOLBTSHRMAPK1 | |
| SCHEMBL23999752 | 0.95 | PDPK1 (0.41) | PDPK1MAPTPOLBTSHRMAPK1 | |
| SCHEMBL26328568 | 0.91 | PDPK1 (0.44) | PDPK1MAPTPOLBTSHRMAPK1 | |
| SCHEMBL23999550 | 0.86 | SYK (0.39) | MAPTPOLBTSHRMAPK1KMT2A | |
| SCHEMBL30180668 | 0.86 | SYK (0.39) | MAPTPOLBTSHRMAPK1KMT2A | |
| SCHEMBL26323193 | 0.86 | MAPT (0.40) | PDPK1MAPTPOLBTSHRMAPK1 | |
| SCHEMBL26323217 | 0.86 | MAPT (0.40) | PDPK1MAPTPOLBTSHRMAPK1 | |
| SCHEMBL24000022 | 0.86 | MAPT (0.39) | MAPTPOLBTSHRMAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295114-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-09-21 | — | — | US | disclosed |
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295114-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | PDPK1 30/4885MAPT 3962/4885POLB 2552/4885 |
| US-20230183226-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | PDPK1 28/4885MAPT 3999/4885POLB 2609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.